Acadia Pharmaceuticals to Report Q1 2026 Earnings on May 6

The pharmaceutical company will host a conference call to discuss the quarterly results.

Apr. 15, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

An extreme close-up photograph of complex pharmaceutical manufacturing equipment, including gears, pipes, and other industrial components, conveying the technical sophistication behind drug development.Acadia Pharmaceuticals' latest financial report will provide investors with a glimpse into the advanced technology and manufacturing processes powering the company's neurological drug pipeline.San Diego Today

Acadia Pharmaceuticals Inc., a biopharmaceutical company focused on developing treatments for neurological and rare diseases, announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. financial markets. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the quarterly results.

Why it matters

As a publicly traded pharmaceutical company, Acadia's quarterly earnings reports provide important insights into the performance and progress of its drug development pipeline, which includes treatments for Parkinson's disease psychosis, Rett syndrome, Alzheimer's disease psychosis, and Lewy body dementia psychosis.

The details

Acadia will report its Q1 2026 financial results on May 6, 2026, after the U.S. markets close. The company will then host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the quarterly results. The webcast will be available on Acadia's website, and a replay will be archived there until August 15, 2026.

  • Acadia will report Q1 2026 financial results on May 6, 2026.
  • Acadia will host a conference call and webcast at 4:30 p.m. Eastern Time on May 6, 2026.

The players

Acadia Pharmaceuticals Inc.

A biopharmaceutical company focused on developing treatments for neurological and rare diseases, including Parkinson's disease psychosis, Rett syndrome, Alzheimer's disease psychosis, and Lewy body dementia psychosis.

Got photos? Submit your photos here. ›

The takeaway

Acadia's upcoming earnings report will provide investors with important updates on the company's drug development pipeline and its progress in addressing underserved neurological and rare disease communities.